Cargando…
肺癌患者阿片类药物应用现状与合理性分析:单中心回顾性研究
BACKGROUND AND OBJECTIVE: Cancer pain affect the physical activity, psychological state and quality of life seriously, and even shortened the survival time of patients. Rational and standard application of opioids could control cancer pain effectively. Since the high incidence of cancer pain in lung...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210091/ https://www.ncbi.nlm.nih.gov/pubmed/32213265 http://dx.doi.org/10.3779/j.issn.1009-3419.2020.102.12 |
_version_ | 1783531208471216128 |
---|---|
collection | PubMed |
description | BACKGROUND AND OBJECTIVE: Cancer pain affect the physical activity, psychological state and quality of life seriously, and even shortened the survival time of patients. Rational and standard application of opioids could control cancer pain effectively. Since the high incidence of cancer pain in lung cancer patients, the status of opioids application should be analyzed to evaluate the rationality of analgesic application in lung cancer patients. METHODS: The clinical data of 305 patients with lung cancer who were hospitalized in Department of Respiratory and Critical Care Medicine of Peking Union Medical College Hospital from June 2018 to June 2019 were analyzed retrospectively. RESULTS: In the analysis of factors affecting the use of opioids in lung cancer patients, age and drug kinds were the main influencing factors. The proportion of male patients was higher than female. Moreover, male patients used more kinds of opioids and were mostly between 60 and 69 years old. The variety and structure of opioids used in lung cancer patients in our hospital met the requirements. Oxycodone hydrochloride prolonged-release tablet has the highest frequency of application, and defined daily cost (DDC) ranked the first with a serial number ratio of 1, which showed good synchronization. The quantity of morphine tablet and morphine injection were low, and the overall breakthrough cancer pain (BTcP) in lung cancer patients was well controlled. The overall application of opioids were reasonable (93.4%), and the unreasonable items mainly included the disposal of BTcP and the unreasonable frequency of opioids, as well as overdose. CONCLUSION: The majority of patients with lung cancer who take opioids are male, and the cancer pain in elderly men are more difficult to control, which needs to pay more attention. The overall application of opioids in the patients with lung cancer pain in our hospital are reasonable, but there are still some problems to focus, such as the disposal of BTcP, the dosage of opioids and the medication of special groups. |
format | Online Article Text |
id | pubmed-7210091 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | 中国肺癌杂志编辑部 |
record_format | MEDLINE/PubMed |
spelling | pubmed-72100912020-05-14 肺癌患者阿片类药物应用现状与合理性分析:单中心回顾性研究 Zhongguo Fei Ai Za Zhi 临床研究 BACKGROUND AND OBJECTIVE: Cancer pain affect the physical activity, psychological state and quality of life seriously, and even shortened the survival time of patients. Rational and standard application of opioids could control cancer pain effectively. Since the high incidence of cancer pain in lung cancer patients, the status of opioids application should be analyzed to evaluate the rationality of analgesic application in lung cancer patients. METHODS: The clinical data of 305 patients with lung cancer who were hospitalized in Department of Respiratory and Critical Care Medicine of Peking Union Medical College Hospital from June 2018 to June 2019 were analyzed retrospectively. RESULTS: In the analysis of factors affecting the use of opioids in lung cancer patients, age and drug kinds were the main influencing factors. The proportion of male patients was higher than female. Moreover, male patients used more kinds of opioids and were mostly between 60 and 69 years old. The variety and structure of opioids used in lung cancer patients in our hospital met the requirements. Oxycodone hydrochloride prolonged-release tablet has the highest frequency of application, and defined daily cost (DDC) ranked the first with a serial number ratio of 1, which showed good synchronization. The quantity of morphine tablet and morphine injection were low, and the overall breakthrough cancer pain (BTcP) in lung cancer patients was well controlled. The overall application of opioids were reasonable (93.4%), and the unreasonable items mainly included the disposal of BTcP and the unreasonable frequency of opioids, as well as overdose. CONCLUSION: The majority of patients with lung cancer who take opioids are male, and the cancer pain in elderly men are more difficult to control, which needs to pay more attention. The overall application of opioids in the patients with lung cancer pain in our hospital are reasonable, but there are still some problems to focus, such as the disposal of BTcP, the dosage of opioids and the medication of special groups. 中国肺癌杂志编辑部 2020-04-20 /pmc/articles/PMC7210091/ /pubmed/32213265 http://dx.doi.org/10.3779/j.issn.1009-3419.2020.102.12 Text en 版权所有©《中国肺癌杂志》编辑部2020 This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/. |
spellingShingle | 临床研究 肺癌患者阿片类药物应用现状与合理性分析:单中心回顾性研究 |
title | 肺癌患者阿片类药物应用现状与合理性分析:单中心回顾性研究 |
title_full | 肺癌患者阿片类药物应用现状与合理性分析:单中心回顾性研究 |
title_fullStr | 肺癌患者阿片类药物应用现状与合理性分析:单中心回顾性研究 |
title_full_unstemmed | 肺癌患者阿片类药物应用现状与合理性分析:单中心回顾性研究 |
title_short | 肺癌患者阿片类药物应用现状与合理性分析:单中心回顾性研究 |
title_sort | 肺癌患者阿片类药物应用现状与合理性分析:单中心回顾性研究 |
topic | 临床研究 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210091/ https://www.ncbi.nlm.nih.gov/pubmed/32213265 http://dx.doi.org/10.3779/j.issn.1009-3419.2020.102.12 |
work_keys_str_mv | AT fèiáihuànzhěāpiànlèiyàowùyīngyòngxiànzhuàngyǔhélǐxìngfēnxīdānzhōngxīnhuígùxìngyánjiū AT fèiáihuànzhěāpiànlèiyàowùyīngyòngxiànzhuàngyǔhélǐxìngfēnxīdānzhōngxīnhuígùxìngyánjiū AT fèiáihuànzhěāpiànlèiyàowùyīngyòngxiànzhuàngyǔhélǐxìngfēnxīdānzhōngxīnhuígùxìngyánjiū AT fèiáihuànzhěāpiànlèiyàowùyīngyòngxiànzhuàngyǔhélǐxìngfēnxīdānzhōngxīnhuígùxìngyánjiū AT fèiáihuànzhěāpiànlèiyàowùyīngyòngxiànzhuàngyǔhélǐxìngfēnxīdānzhōngxīnhuígùxìngyánjiū |